Cansino Biotech develops and commercializes human vaccines for more than ten infectious disease indications, using five proprietary platforms such as viral‑vector, mRNA, synthetic, protein‑VLP, and advanced formulation technologies. The company manufactures vaccines in GMP‑certified facilities in China and partners with regional producers to supply affordable, high‑quality vaccines—including licensed products for pertussis, meningococcal disease, pneumococcal disease, COVID‑19, and Ebola—to national immunization programs and public health agencies worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Access to safe, effective vaccines against infectious diseases is limited by complex manufacturing, distribution challenges, and the need for innovative platforms to address emerging pathogens and diverse regional requirements.
Solution
Cansino Biotech develops and commercializes a portfolio of human vaccines targeting over ten infectious disease indications, leveraging five proprietary technology platforms—including viral vector, synthetic, protein‑VLP, mRNA, and advanced formulation technologies. The company produces vaccines in large‑scale, GMP‑certified facilities in China and partners with local manufacturers in Mexico, Malaysia, Pakistan and other regions to ensure regional supply. Its product lineup includes licensed vaccines for pertussis, meningococcal disease, pneumococcal disease, COVID‑19 (injectable and inhaled), Ebola, and a pipeline of additional candidates. By integrating modern platform technologies with global manufacturing and distribution networks, Cansino delivers high‑quality, affordable vaccines to meet both routine immunization needs and rapid responses to pandemics.
Target Audience
Primary customers are national immunization programs, public health agencies, and private healthcare providers in China, Southeast Asia, the Middle East, Latin America and other emerging markets seeking licensed, high‑quality vaccines for routine and outbreak immunization.
Features
- Viral‑vector platform (Ad5) enabling rapid development of COVID‑19, Ebola and other recombinant vaccines.
- mRNA platform with scalable, GMP‑approved manufacturing and a proprietary LNP delivery system for multivalent influenza candidates.
- Synthetic and protein‑VLP platforms that produce high‑purity polysaccharide‑protein conjugate vaccines (e.g., 13‑valent pneumococcal, 4‑valent meningococcal).
- Advanced formulation and delivery technologies, including inhalable aerosol vaccines (e.g., inhaled COVID‑19 vaccine) and preservative‑free, phenol‑free formulations.
- Dual‑carrier (CRM197/TT) design for 13‑valent pneumococcal vaccine to reduce carrier‑induced immune interference.
- Integrated global supply chain with smart cold‑chain logistics, automated warehousing (1 × 10⁴ pallets, ~1.5 × 10⁸ vials) and AEO‑certified export/import processes.
- Established regulatory pathways with WHO pre‑qualification, EU GMP certification, and emergency use authorizations in multiple countries.